dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: S1: Chymotrypsin (type: enzyme)
Target: coagulation factor XI

Ligand: abelacimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 11.329999923706055 pKd
Reference (Journal): MAA868 locks factor XIa in a zymogen-like state.
Published in: Blood
Target family: S1: Chymotrypsin (type: enzyme)
Target: tryptase gamma 1

Ligand: WX-UK1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.199999809265137 pKi
Reference (Journal): 3-Amidinophenylalanine-based inhibitors of urokinase.
Published in: Bioorg Med Chem Lett
Target family: S1: Chymotrypsin (type: enzyme)
Target: tryptase alpha/beta 1

Ligand: RWJ-56423 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8 pKi
Reference (Journal): Potent, small-molecule inhibitors of human mast cell tryptase. Antiasthmatic action of a dipeptide-based transition-state analogue containing a benzothiazole ketone.
Published in: J Med Chem

Ligand: nafamostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: Japan only
Primary target: yes
Median affinity: 10 pIC50
Reference (Journal): Nafamostat mesilate is an extremely potent inhibitor of human tryptase.
Published in: J Pharmacol Sci

Ligand: gabexate (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: Japan
Primary target: yes
Median affinity: 8.470000267028809 pIC50
Reference (Journal): Selective inhibition of human mast cell tryptase by gabexate mesylate, an antiproteinase drug.
Published in: Biochem Pharmacol
Target family: S1: Chymotrypsin (type: enzyme)
Target: transmembrane serine protease 6

Ligand: inhibitor 1 [Colombo et al., 2012] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.479999542236328 pKi
Reference (Journal): Design and synthesis of potent, selective inhibitors of matriptase.
Published in: ACS Med Chem Lett
Target family: S1: Chymotrypsin (type: enzyme)
Target: transmembrane serine protease 2

Ligand: otamixaban (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.210000038146973 pIC50
Reference (Journal): Discovery of TMPRSS2 Inhibitors from Virtual Screening as a Potential Treatment of COVID-19.
Published in: ACS Pharmacol Transl Sci

Ligand: nafamostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: Japan only
Primary target: no
Median affinity: 7 pIC50
Reference (Journal): Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay.
Published in: Antimicrob Agents Chemother

Ligand: N-0385 (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.720000267028809 pIC50
Reference (Journal): A&#xfeff; TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic.
Published in: Nature

Ligand: MM3122 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.369999885559082 pIC50
Reference (Journal): A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells
Published in: bioRxiv

Ligand: I-432 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.050000190734863 pKi
Reference (Journal): In vitro characterization of TMPRSS2 inhibition in IPEC-J2 cells.
Published in: J Enzyme Inhib Med Chem

Ligand: compound 5 [PMID: 21741839] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pKi
Reference (Journal): Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT.
Published in: Bioorg Med Chem Lett

Ligand: camostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Primary target: no
Median affinity: 6 pIC50
Reference (Journal): Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay.
Published in: Antimicrob Agents Chemother
Target family: S1: Chymotrypsin (type: enzyme)
Target: transmembrane serine protease 15

Ligand: sucunamostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.270000457763672 pIC50
Reference (Journal): Discovery and characterization of a small-molecule enteropeptidase inhibitor, SCO-792.
Published in: Pharmacol Res Perspect

Ligand: sucunamostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.34000015258789 pIC50
Reference (Journal): Discovery and characterization of a small-molecule enteropeptidase inhibitor, SCO-792.
Published in: Pharmacol Res Perspect
Target family: S1: Chymotrypsin (type: enzyme)
Target: transmembrane serine protease 11D

Ligand: inhibitor 1 [Colombo et al., 2012] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.079999923706055 pKi
Reference (Journal): Design and synthesis of potent, selective inhibitors of matriptase.
Published in: ACS Med Chem Lett

Ligand: compound 5 [PMID: 21741839] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.71999979019165 pKi
Reference (Journal): Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT.
Published in: Bioorg Med Chem Lett
Target family: S1: Chymotrypsin (type: enzyme)
Target: ST14 transmembrane serine protease matriptase

Ligand: N-0385 (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.59000015258789 pKi
Reference (Patent): Matriptase inhibitors and uses thereof

Ligand: inhibitor 1 [Colombo et al., 2012] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 10.960000038146973 pKi
Reference (Journal): Design and synthesis of potent, selective inhibitors of matriptase.
Published in: ACS Med Chem Lett

Ligand: I-432 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pKi
Reference (Journal): In vitro characterization of TMPRSS2 inhibition in IPEC-J2 cells.
Published in: J Enzyme Inhib Med Chem

Ligand: compound 4d [PMID: 25489658] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.849999904632568 pIC50
Reference (Journal): Toward the first class of suicide inhibitors of kallikreins involved in skin diseases.
Published in: J Med Chem

Ligand: compound 3 [PMID: 23849879] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.239999771118164 pIC50
Reference (Journal): 1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases.
Published in: Bioorg Med Chem Lett
Target family: S1: Chymotrypsin (type: enzyme)
Target: serine protease 8

Ligand: B3C (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.920000076293945 pKi
Reference (Journal): Discovery of inhibitors of the channel-activating protease prostasin (CAP1/PRSS8) utilizing structure-based design.
Published in: Bioorg Med Chem Lett
Target family: S1: Chymotrypsin (type: enzyme)
Target: serine protease 3

Ligand: BPTI-K15R/R17G (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.229999542236328 pKi
Reference (Journal): The P(2)' residue is a key determinant of mesotrypsin specificity: engineering a high-affinity inhibitor with anticancer activity.
Published in: Biochem J
Target family: S1: Chymotrypsin (type: enzyme)
Target: serine protease 1

Ligand: RWJ-56423 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.09000015258789 pKi
Reference (Journal): Potent, small-molecule inhibitors of human mast cell tryptase. Antiasthmatic action of a dipeptide-based transition-state analogue containing a benzothiazole ketone.
Published in: J Med Chem

Ligand: nafamostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: Japan only
Primary target: yes
Median affinity: 7.769999980926514 pIC50
Reference (Journal): 2-amino-4H-3,1-benzoxazin-4-ones as inhibitors of C1r serine protease.
Published in: J Med Chem

Ligand: compound 9 [PMID: 3514912] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.710000038146973 pIC50
Reference (Journal): Synthesis and inhibition of human acrosin and trypsin and acute toxicity of aryl 4-guanidinobenzoates.
Published in: J Med Chem

Ligand: camostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Primary target: yes
Median affinity: 7.300000190734863 pIC50
Reference (Journal): New orally active serine protease inhibitors.
Published in: J Med Chem
Target family: S1: Chymotrypsin (type: enzyme)
Target: protein C, inactivator of coagulation factors Va and VIIIa

Ligand: compound 37 [PMID: 24418773] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.400000095367432 pKi
Reference (Journal): Design, synthesis, and SAR of a series of activated protein C (APC) inhibitors with selectivity against thrombin for the treatment of haemophilia.
Published in: Bioorg Med Chem Lett
Target family: S1: Chymotrypsin (type: enzyme)
Target: proteinase 3

Ligand: compound 4g [PMID: 22595175] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 5.849999904632568 pIC50
Reference (Journal): N-Acyl and N-sulfonyloxazolidine-2,4-diones are pseudo-irreversible inhibitors of serine proteases.
Published in: Bioorg Med Chem Lett

Ligand: compound 11 [PMID: 29442501] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.270000457763672 pKi
Reference (Journal): Exploiting the S4-S5 Specificity of Human Neutrophil Proteinase 3 to Improve the Potency of Peptidyl Di(chlorophenyl)-phosphonate Ester Inhibitors: A Kinetic and Molecular Modeling Analysis.
Published in: J Med Chem

Ligand: azapro-3 (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.820000171661377 pKi
Reference (Journal): A selective reversible azapeptide inhibitor of human neutrophil proteinase 3 derived from a high affinity FRET substrate.
Published in: Biochem Pharmacol
Target family: S1: Chymotrypsin (type: enzyme)
Target: plasminogen activator, urokinase

Ligand: WX-UK1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.190000057220459 pKi
Reference (Journal): Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1.
Published in: Thromb Haemost

Ligand: WX-UK1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 6.4 pIC50
Reference (Journal): 3-Amidinophenylalanine-based inhibitors of urokinase.
Published in: Bioorg Med Chem Lett

Ligand: upamostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  -

Ligand: UK-356202 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.4 pIC50
Reference (Journal): Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines.
Published in: Bioorg Med Chem Lett

Ligand: compound 4 [PMID: 18163548] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.7 pIC50
Reference (Journal): Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator.
Published in: J Med Chem

Ligand: BB2-50F (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.739999771118164 pKi
Reference (Journal): 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
Published in: J Med Chem
Target family: S1: Chymotrypsin (type: enzyme)
Target: plasminogen activator, tissue type

Ligand: Dup-714 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.239999771118164 pKi
Reference (Journal): (N-acyl-N-alkyl)glycyl borolysine analogs: A new class of potent thrombin inhibitors.
Published in: Bioorg Med Chem Lett
Target family: S1: Chymotrypsin (type: enzyme)
Target: plasminogen

Ligand: WX-UK1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.840000152587891 pKi
Reference (Journal): Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1.
Published in: Thromb Haemost

Ligand: tranexamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: yes
Approval source: FDA (1986)
Primary target: yes
Median affinity: 3.5999999046325684 pIC50
Reference (Journal): Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation.
Published in: J Thromb Haemost

Ligand: bis-triazole derivative 10 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9.1 pKi
Reference (Journal): A new strategy for the development of highly potent and selective plasmin inhibitors.
Published in: J Med Chem

Ligand: aprotinin (Peptide)
Interaction type: Inhibitor
Action: Binding
Ligand approved: yes
Approval source: FDA (1993)
Primary target: yes
Median affinity: 6.800000190734863 pIC50
Reference (Journal): Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation.
Published in: J Thromb Haemost

Ligand: 6-aminocaproic acid (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: yes
Approval source: FDA (1964)
Primary target: yes
Median affinity: 4.400000095367432 pIC50
Reference (Journal): Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein-Protein Interaction.
Published in: ACS Med Chem Lett
Target family: S1: Chymotrypsin (type: enzyme)
Target: kallikrein related peptidase 8

Ligand: compound 32 [PMID: 31675166] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.699999809265137 pIC50
Reference (Journal): Synthesis and Structure-Activity Relationships of N-(4-Benzamidino)-Oxazolidinones: Potent and Selective Inhibitors of Kallikrein-Related Peptidase 6.
Published in: ChemMedChem
Target family: S1: Chymotrypsin (type: enzyme)
Target: kallikrein related peptidase 7

Ligand: compound 4d [PMID: 25489658] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.190000057220459 pIC50
Reference (Journal): Toward the first class of suicide inhibitors of kallikreins involved in skin diseases.
Published in: J Med Chem

Ligand: compound 3 [PMID: 23849879] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.400000095367432 pIC50
Reference (Journal): 1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases.
Published in: Bioorg Med Chem Lett
Target family: S1: Chymotrypsin (type: enzyme)
Target: kallikrein related peptidase 6

Ligand: DKFZ‐251 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.889999866485596 pIC50
Reference (Journal): Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity.
Published in: J Med Chem

Ligand: compound 5 {PMID: 24900446] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.820000171661377 pIC50
Reference (Journal): Virtual Screening and X-ray Crystallography for Human Kallikrein 6 Inhibitors with an Amidinothiophene P1 Group.
Published in: ACS Med Chem Lett

Ligand: compound 32 [PMID: 31675166] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.600000381469727 pIC50
Reference (Journal): Synthesis and Structure-Activity Relationships of N-(4-Benzamidino)-Oxazolidinones: Potent and Selective Inhibitors of Kallikrein-Related Peptidase 6.
Published in: ChemMedChem
Target family: S1: Chymotrypsin (type: enzyme)
Target: kallikrein related peptidase 5

Ligand: compound 4d [PMID: 25489658] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.039999961853027 pIC50
Reference (Journal): Toward the first class of suicide inhibitors of kallikreins involved in skin diseases.
Published in: J Med Chem

Ligand: compound 3 [PMID: 23849879] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.570000171661377 pIC50
Reference (Journal): 1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases.
Published in: Bioorg Med Chem Lett
Target family: S1: Chymotrypsin (type: enzyme)
Target: kallikrein related peptidase 4

Ligand: compound 33 [PMID: 19908842] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.010000228881836 pIC50
Reference (Journal): Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB.
Published in: J Med Chem

Ligand: compound 32 [PMID: 31675166] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.800000190734863 pIC50
Reference (Journal): Synthesis and Structure-Activity Relationships of N-(4-Benzamidino)-Oxazolidinones: Potent and Selective Inhibitors of Kallikrein-Related Peptidase 6.
Published in: ChemMedChem
Target family: S1: Chymotrypsin (type: enzyme)
Target: kallikrein related peptidase 3

Ligand: compound 20 [PMID: 23692593] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.139999866485596 pKi
Reference (Journal): Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors.
Published in: J Med Chem
Target family: S1: Chymotrypsin (type: enzyme)
Target: kallikrein related peptidase 2

Ligand: peptide KLK2b(c1) (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity:  -
Reference (Journal): Activity and stability of human kallikrein-2-specific linear and cyclic peptide inhibitors.
Published in: J Pept Sci

Ligand: hK2p01 derivative KLK2 inhibitor (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 5.849999904632568 pKi
Reference (Journal): Novel peptide inhibitors of human kallikrein 2.
Published in: J Biol Chem
Target family: S1: Chymotrypsin (type: enzyme)
Target: kallikrein related peptidase 14

Ligand: compound 4d [PMID: 25489658] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.539999961853027 pIC50
Reference (Journal): Toward the first class of suicide inhibitors of kallikreins involved in skin diseases.
Published in: J Med Chem

Ligand: compound 3 [PMID: 23849879] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.889999866485596 pIC50
Reference (Journal): 1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases.
Published in: Bioorg Med Chem Lett
Target family: S1: Chymotrypsin (type: enzyme)
Target: kallikrein B1

Ligand: sebetralstat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.220000267028809 pIC50
Reference (Journal): Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema.
Published in: J Med Chem

Ligand: milvexian (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.360000133514404 pKi
Reference (Journal): Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy.
Published in: J Med Chem

Ligand: lanadelumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: EMA & FDA (2018)
Primary target: yes
Median affinity: 10.050000190734863 pIC50
Reference (Patent): Plasma kallikrein binding proteins.

Ligand: compound 11 [PMID: 16413183] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.300000190734863 pKi
Reference (Journal): Small molecule inhibitors of plasma kallikrein.
Published in: Bioorg Med Chem Lett

Ligand: berotralstat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2020), EMA (2021)
Primary target: no
Median affinity:  pKi
Reference (Patent): Human plasma kallikrein inhibitors

Ligand: avoralstat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pIC50
Reference (Journal): Structures of full-length plasma kallikrein bound to highly specific inhibitors describe a new mode of targeted inhibition.
Published in: J Struct Biol
Target family: S1: Chymotrypsin (type: enzyme)
Target: kallikrein 1

Ligand: example 131 [WO2009133348] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.270000457763672 pIC50
Reference (Patent): Aminopyridine derivatives.
Target family: S1: Chymotrypsin (type: enzyme)
Target: HtrA serine peptidase 1

Ligand: galegenimab (Antibody)
Interaction type: Antibody
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.229999542236328 pKd
Reference (Patent): Anti-htra1 antibodies and methods of use thereof
Target family: S1: Chymotrypsin (type: enzyme)
Target: granzyme B

Ligand: compound 20 [PMID:12127536] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.149999618530273 pKi
Reference (Journal): Discovery of potent, selective human granzyme B inhibitors that inhibit CTL mediated apoptosis.
Published in: Bioorg Med Chem Lett